Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Inclusion Criteria: * Histologically confirmed high-risk or relapsed solid tumors or brain tumors, including: * Metastatic or relapsed Ewing's sarcoma * Metastatic or relapsed rhabdomyosarcoma * Refractory Wilms' tumor * Diffuse anaplastic Wilms' tumor * Stage III or IV neuroblastoma * Recurrent retinoblastoma * Metastatic or relapsed germ cell tumors * Metastatic or relapsed other soft tissue sarcomas * Small cell ovarian sarcoma * Metastatic or relapsed primitive neuroectodermal tumors of the bone * Recurrent brain tumors * Desmoplastic small round cell tumors * Recurrent or metastatic chordomas * Metastatic or relapsed hepatoblastoma * Patients receive peripheral blood stem cell transplantation only if in complete remission or in very good partial remission with no disease progression * Must have radiologic, nuclear image, or histologic verification of relapse * Age 1 to 45 * Performance status:Karnofsky 70-100% * Absolute neutrophil count greater than 1,000/mm\^3 * Platelet count greater than 100,000/mm\^3 * Hemoglobin count at least 10 g/dL * Bilirubin less than 2 times upper limit of normal (ULN) * SGOT or SGPT less than 2.5 times ULN * Creatinine less than 2 times ULN * Creatinine clearance greater than 70 mL/min * Cardiac shortening fraction greater than 30% * Cardiac ejection fraction greater than 45% * At least 1 week since prior hematopoietic growth factor and recovered * At least 3 weeks since prior chemotherapy (6 weeks for nitrosour…